EMA issues guidance for global development of antimicrobial medicines

  27 May 2022

The European Medicines Agency (EMA) has published its final revised guideline on the evaluation of human medicines for the treatment of bacterial infections. The guidance forms part of EMA’s efforts to support a global approach to the development of new antimicrobial medicines.

Antimicrobial resistance (AMR) – the ability of microorganisms to resist antimicrobial treatments, especially antibiotics – has a direct impact on the health of people and animals. In the European Union (EU) alone, it is responsible for an estimated 33,000 deaths per year. Its effects are also felt on a financial level worldwide, with AMR estimated to cost the EU €1.5 billion per year in healthcare costs and productivity losses.

Author(s): European Pharmaceutical Review
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed